European Journal of Medicinal Chemistry (2020)
Update date:2022-08-02
Topics:
Chen, Tao
Fang, Wei-Rong
Huang, Wei
Li, Yun-Man
Liu, Peng-Fei
Zhuo, Lin-Sheng
A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.
View MoreContact:+86-21-61318535
Address:Building 29,No.2139 Xizha Road, Fengxian District, Shanghai
KangZhiYuan Pharmaceutical Company Limited
Contact:(Sabrina)86-20-85273232
Address:4th floor, building B, Dadi industry zone, Tangxia, Tianhe, Guangzhou, China
Hangzhou Eastbiopharm Co.,Ltd.
Contact:+86-571-88931780
Address:Hangzhou,China
Shanggao Ruiya Fine Chemicals Co., Ltd
Contact:+86-795-2592103
Address:Xingguang Nanlu,Shanggao County Industry Park
HAINAN JINYING IMPORT AND EXPORT CO. LTD
Contact:+86-898-32875423
Address:A SECTION 19TH FL, TIMES SQUARE, NO.2 GUO MAO AVENUE HAIKOU, HAINAN, P. R. OF CHINA
Doi:10.1080/00397911.2011.558969
(2012)Doi:10.1039/c2ob25990g
(2012)Doi:10.1021/jm00054a009
(1993)Doi:10.1021/jo00034a016
(1992)Doi:10.1021/jm00088a008
(1992)Doi:10.1021/ja00469a056
(1978)